Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04823702 · ClinicalTrials.gov registry record · Phase 1
Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function
A Phase 1 study of Impaired Hepatic Function, sponsored by NGM Biopharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 3
- Study locations
NCT04823702 is a Phase 1 study of Impaired Hepatic Function that has completed, run by NGM Biopharmaceuticals. The registered enrollment target is 36 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT04823702, a Phase 1 study of Impaired Hepatic Function, has completed, sponsored by NGM Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function
Conditions Studied
Interventions
- BIOLOGICAL Aldafermin
Study Locations (3)
Florida
- NGM Clinical Study Site 110 - Miami
- NGM Clinical Study Site 111 - Orlando
Texas
- NGM Clinical Study Site 113 - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2021-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04823702
The ClinicalTrials.gov registry entry for NCT04823702 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NGM Biopharmaceuticals, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Impaired Hepatic Function appearing as the primary indexed condition, and to 1 intervention - of which Aldafermin is the first listed.
NCT04823702 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT04823702 about?
NCT04823702 is a clinical study titled "Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function". This is an evaluation of Aldafermin (NGM282) in an open-label, single-dose and parallel group study in participants with Impaired Hepatic Function
What is the current status of trial NCT04823702?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2021-04-01. Estimated completion is 2021-11-19.
What conditions does trial NCT04823702 study?
This clinical trial studies the following conditions: Impaired Hepatic Function.
What interventions are being tested in trial NCT04823702?
The interventions under investigation include: Aldafermin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04823702?
This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04823702 being conducted?
This trial has 3 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Impaired Hepatic Function
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.